ArticleDiabetes, obesity & metabolism2025
Investigating multimorbidity trajectories in people living with MASLD diagnosis: A trajectory analysis using the UK Biobank.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict cardiometabolic multimorbidity development and progression in metabolic dysfunction-associated steatotic liver disease individuals: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Capturing systemic disease burden in MASLD: Toward integrated liver-kidney-cardiovascular economic models: Reply to correspondence on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".Clinical and molecular hepatology · 2026Article
- Associations of insulin resistance-related indices with the risk and progression of cardiometabolic multimorbidity in individuals with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Associations between the C-reactive protein-triglyceride-glucose index and its derived indices and the incidence and progression of cardiometabolic multimorbidity in participants with metabolic dysfunction-associated steatotic liver disease: a large-scale prospective cohort study.Cardiovascular diabetology · 2026Article
- Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review.EClinicalMedicine · 2026Review
- Nationwide Big Data Studies of Endocrine Diseases Using the Korean National Health Information Database: Research Trends and Standardization of Operational Definitions.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Investigating multimorbidity trajectories in people living with MASLD diagnosis: A trajectory analysis using the UK Biobank.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern, and its presence increases the risk of multi-system diseases. This study aimed to investigate the multimorbidity trajectories of chronic diseases in people living with MASLD.
methodsWe identified 137 859 MASLD patients in UK Biobank and used 'propensity score matching' to match an equal number of non-MASLD controls. Diseases were reclassified into 472 categories based on the International Classification of Diseases, Tenth Revision (ICD-10) chapters. Multimorbidity trajectories post-MASLD diagnosis were mapped using validated trajectory analysis. We introduced the 'Multimorbidity Trajectory Position Index (MTPI)' to denote a disease's position across trajectories, highlighting its temporal pattern.
resultsParticipants had a median age of 59 (52-64) years, with 65.6% being male. Over 13 years of follow-up, Phenome-wide association analysis (PheWAS) identified 128 diseases with elevated risks post-MASLD diagnosis, with obesity (HR: 8.77, 95% CI: 8.37-9.18), diabetes (HR: 4.34, 95% CI: 4.15-4.53), and sleep disorders (HR: 3.21, 95% CI: 3.01-3.42) showing the strongest associations. Trajectory analysis revealed 6637 common trajectories involving 69 diseases, grouped into metabolic, inflammatory, and cardiovascular clusters. These clusters are linked to downstream conditions, with intermediary diseases such as hypertension, diabetes, and inflammatory arthritis, ultimately leading to electrolyte imbalances and sepsis. MTPI demonstrated a gradient in disease progression, with early-stage conditions showing low values, mid-stage conditions moderate values, and late-stage conditions high values.
conclusionPeople living with MASLD demonstrated multimorbidity trajectories involving co-occurrence of metabolic diseases, chronic inflammation, and cardiovascular diseases. If replicated, these pathways may serve as promising targets to improve late-life health in individuals with MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.